Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA Transcript

Core Viewpoint - Jazz Pharmaceuticals presented groundbreaking data from the Phase III HERIZON-GEA-01 clinical trial for zanidatamab in combination with chemotherapy for first-line HER2-positive GEA patients at a recent symposium [2]. Group 1: Clinical Trial Insights - The HERIZON-GEA-01 trial assesses zanidatamab in combination with chemotherapy, with or without tislelizumab, targeting first-line HER2-positive GEA patients [2][3]. - The presentation of the trial data occurred at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, highlighting the significance of the findings [2]. Group 2: Leadership and Expertise - Dr. Geoff Ku, an associate attending physician at Memorial Sloan Kettering Cancer Center, participated in the call to discuss the HERIZON data, indicating the involvement of leading experts in the field [3].